A phase II study to assess the hemodynamic effects of istaroxime, a novel lusinotropic agent, in patients hospitalized with worsening heart failure and a reduced left ventricular systolic function

Trial Profile

A phase II study to assess the hemodynamic effects of istaroxime, a novel lusinotropic agent, in patients hospitalized with worsening heart failure and a reduced left ventricular systolic function

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Istaroxime (Primary)
  • Indications Acute heart failure; Heart failure; Left ventricular dysfunction
  • Focus Therapeutic Use
  • Acronyms HORIZON-HF
  • Most Recent Events

    • 01 Apr 2008 Results have been presented (ACC 2008).
    • 17 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top